Table 1.
Results of microarray studies after IPA analysis.
| Ingenuity (IPA) Canonical Pathways | Molecules |
|---|---|
| (A) GD patients vs. controls | |
| Interferon Signalling | IFIT3, IFIT1**, OAS1, IFI6, IRF9, STAT1, TAP1, ISG15 |
| Activation of IRF by Cytosolic Pattern Recognition Receptors | IFIH1, IRF9, STAT1, IFIT2, ISG15 |
| Protein Ubiquitination Pathway | UCHL1, B2M, PSME1, DNAJB4, TAP1, UBE2L6, UCHL3 |
| Oncostatin M Signalling | PLAU, STAT1 |
| Coagulation System | PLAU, TFPI |
| Hepatic Fibrosis/Hepatic Stellate Cell Activation | LY96, COL4A5, IGFBP5, STAT1 |
| Adipogenesis pathway | LPIN1, SMAD9, TXNIP |
| Parkinson’s Signalling | UCHL1 |
| Glioma Invasiveness Signalling | RND3, PLAU |
| VDR/RXR Activation | IGFBP5, KLF4 |
| Inhibition of Matrix Metalloproteases | THBS2 |
| LXR/RXR Activation | LY96, MYLIP |
| Glucocorticoid Receptor Signalling | BCL2L1, PLAU, STAT1 |
| (B) GD patients vs. NPC patients | |
| Interferon Signalling | IFIT3,IFIT1,OAS1,MX1,STAT1,TAP1,ISG15 |
| Protein Ubiquitination Pathway | PSMA6,DNAJB4,HSPA9,PSME2,TAP1,UCHL3, UCHL1,USO1, HSP90B1,HLA-C,PSMA4,HSPB7, PSMD14,PSMC2,UBE2E1 |
| Activation of IRF by Cytosolic Pattern Recognition Receptors | STAT1,NFKB1,IFIT2,ISG15 |
| Glioma Invasiveness Signalling | RND3,RHOB,MMP2,PLAU |
| Oncostatin M Signalling | PLAU,STAT1 |
| Coagulation System | PROS1,PLAU |
| IL-17A Signalling in Fibroblasts | FOS***, NFKB1 |
| Prostanoid Biosynthesis | PTGIS |
| Glucocorticoid Receptor Signalling | FOS,HSP90B1,HSPA9,POLR2H,PLAU,STAT1,NFKB1 |
| Parkinson’s Signalling | UCHL1 |
Cellular canonical pathways with most differentially expressed genes. Comparison ‘GD patients vs. controls’ (part A) and comparison ‘GD patients vs. NPC patients’ (part B)*. *Data were analysed through the use of IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis).
**Bolded and underlined are genes with most enhanced or inhibited expression after microarray study. *** and 64 other pathways in which FOS was involved, see Supplementary Table S4 part A (all canonical pathways with changed expression).